دورية أكاديمية
أعرض في EDS

Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.

التفاصيل البيبلوغرافية
العنوان: Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge.
المؤلفون: Hsieh CL; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA., Leist SR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Miller EH; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.; Department of Medicine-Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY, 10461, USA., Zhou L; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA., Powers JM; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Tse AL; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA., Wang A; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA., West A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Zweigart MR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Schisler JC; McAllister Heart Institute and Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Jangra RK; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.; Department of Microbiology and Immunology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA, 71103, USA., Chandran K; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., McLellan JS; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA. jmclellan@austin.utexas.edu.
المصدر: Nature communications [Nat Commun] 2024 Feb 20; Vol. 15 (1), pp. 1553. Date of Electronic Publication: 2024 Feb 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: SARS-CoV-2* , COVID-19*/prevention & control, Female ; Animals ; Humans ; Mice ; COVID-19 Vaccines ; Antigens, Viral/genetics ; Mice, Inbred BALB C ; Spike Glycoprotein, Coronavirus/genetics ; Antibodies, Neutralizing ; Antibodies, Viral
مستخلص: Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that offers a greater breadth of protection against current and future VOCs would eliminate the need to reformulate COVID-19 vaccines. Here, we rationally engineer the sequence-conserved S2 subunit of the SARS-CoV-2 spike protein and characterize the resulting S2-only antigens. Structural studies demonstrate that the introduction of interprotomer disulfide bonds can lock S2 in prefusion trimers, although the apex samples a continuum of conformations between open and closed states. Immunization with prefusion-stabilized S2 constructs elicits broadly neutralizing responses against several sarbecoviruses and protects female BALB/c mice from mouse-adapted SARS-CoV-2 lethal challenge and partially protects female BALB/c mice from mouse-adapted SARS-CoV lethal challenge. These engineering and immunogenicity results should inform the development of next-generation pan-coronavirus therapeutics and vaccines.
(© 2024. The Author(s).)
References: ACS Cent Sci. 2022 Dec 28;8(12):1646-1663. (PMID: 36589893)
Cell Host Microbe. 2019 Nov 13;26(5):623-637.e8. (PMID: 31653484)
Nat Commun. 2022 Aug 4;13(1):4539. (PMID: 35927266)
Cell Host Microbe. 2023 Jan 11;31(1):97-111.e12. (PMID: 36347257)
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14. (PMID: 23793146)
Nature. 2020 Aug;584(7821):437-442. (PMID: 32555388)
Science. 2022 Aug 12;377(6607):735-742. (PMID: 35857703)
Science. 2021 Aug 27;373(6558):991-998. (PMID: 34214046)
Nucleic Acids Res. 2016 Jul 8;44(W1):W344-50. (PMID: 27166375)
Science. 2022 Aug 5;377(6606):eabq0839. (PMID: 35857620)
Nat Commun. 2022 Mar 14;13(1):1299. (PMID: 35288548)
Am J Hematol. 2023 May;98(5):E123-E126. (PMID: 36810791)
Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2208425120. (PMID: 36669119)
Nat Rev Immunol. 2023 Jun;23(6):381-396. (PMID: 36536068)
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. (PMID: 28807998)
Sci Transl Med. 2022 Sep 28;14(664):eabo5070. (PMID: 35857635)
Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6. (PMID: 32738193)
Vaccines (Basel). 2020 Jul 12;8(3):. (PMID: 32664628)
Cell. 2020 Nov 12;183(4):1070-1085.e12. (PMID: 33031744)
Sci Immunol. 2021 Oct 15;6(64):eabj2901. (PMID: 34652962)
Cell Host Microbe. 2022 Apr 13;30(4):545-555.e4. (PMID: 35364015)
Lancet Infect Dis. 2023 Aug;23(8):880-881. (PMID: 37088097)
Cell Res. 2022 Dec;32(12):1068-1085. (PMID: 36357786)
Nat Methods. 2017 Mar;14(3):290-296. (PMID: 28165473)
mBio. 2019 Feb 26;10(1):. (PMID: 30808695)
Science. 2012 Sep 14;337(6100):1343-8. (PMID: 22878502)
Sci Transl Med. 2022 Mar 23;14(637):eabi9215. (PMID: 35133175)
Science. 2021 Feb 12;371(6530):735-741. (PMID: 33436524)
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):. (PMID: 35149556)
Nat Commun. 2019 May 8;10(1):2105. (PMID: 31068578)
Cell. 2023 Jan 19;186(2):279-286.e8. (PMID: 36580913)
Annu Rev Virol. 2016 Sep 29;3(1):237-261. (PMID: 27578435)
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18754-18763. (PMID: 32690707)
Science. 2020 Sep 18;369(6510):1501-1505. (PMID: 32703906)
Nat Med. 2014 Feb;20(2):143-51. (PMID: 24412922)
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11931-11936. (PMID: 27698132)
Cell Rep. 2023 Apr 25;42(4):112326. (PMID: 37000623)
Cell Rep. 2021 Jan 26;34(4):108682. (PMID: 33503432)
Nat Commun. 2021 Mar 17;12(1):1715. (PMID: 33731724)
Science. 2021 Sep 03;373(6559):1109-1116. (PMID: 34344823)
Nat Struct Mol Biol. 2022 Mar;29(3):229-238. (PMID: 35236990)
Sci Immunol. 2023 Mar 17;8(81):eade0958. (PMID: 36701425)
Science. 2022 Aug 12;377(6607):728-735. (PMID: 35857439)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Elife. 2023 Mar 21;12:. (PMID: 36942851)
MedComm (2020). 2023 Mar 15;4(2):e239. (PMID: 36938325)
Immunity. 2023 Mar 14;56(3):669-686.e7. (PMID: 36889306)
Curr Opin Struct Biol. 2022 Jun;74:102385. (PMID: 35533563)
Nat Struct Mol Biol. 2021 Jun;28(6):478-486. (PMID: 33981021)
J Clin Invest. 2016 Feb;126(2):605-10. (PMID: 26731473)
PLoS Pathog. 2020 Oct 9;16(10):e1008942. (PMID: 33035266)
Nat Med. 2015 Sep;21(9):1065-70. (PMID: 26301691)
Nat Commun. 2021 Aug 10;12(1):4817. (PMID: 34376662)
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. (PMID: 15572765)
PLoS Pathog. 2007 Jan;3(1):e5. (PMID: 17222058)
Cell Rep. 2021 Nov 2;37(5):109929. (PMID: 34710354)
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54. (PMID: 12393927)
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81. (PMID: 21460445)
Small. 2022 Jun;18(25):e2200836. (PMID: 35607768)
Cell Rep. 2022 Sep 20;40(12):111399. (PMID: 36130517)
Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):519-530. (PMID: 29872003)
Nat Med. 2023 Feb;29(2):344-347. (PMID: 36473500)
mBio. 2015 Jun 30;6(4):e00801. (PMID: 26126854)
Science. 2015 Sep 18;349(6254):1301-6. (PMID: 26303961)
Cell. 2019 May 16;177(5):1124-1135.e16. (PMID: 31100267)
Commun Biol. 2023 Dec 11;6(1):1250. (PMID: 38082099)
Cell. 2019 May 16;177(5):1136-1152.e18. (PMID: 31100268)
Cell Mol Immunol. 2021 Nov;18(11):2563-2565. (PMID: 34645942)
Nat Rev Microbiol. 2023 Mar;21(3):162-177. (PMID: 36653446)
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. (PMID: 19461840)
Cell. 2020 Nov 12;183(4):1024-1042.e21. (PMID: 32991844)
N Engl J Med. 2023 Jan 19;388(3):214-227. (PMID: 36652353)
J Virol. 2003 Aug;77(16):8801-11. (PMID: 12885899)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
N Engl J Med. 2021 May 13;384(19):1824-1835. (PMID: 33440088)
Sci Transl Med. 2022 Jul 27;14(655):eabn3715. (PMID: 35895836)
معلومات مُعتمدة: K12 TR004411 United States TR NCATS NIH HHS; P01 AI127335 United States AI NIAID NIH HHS; P20 GM134974 United States GM NIGMS NIH HHS; INV-031624 United States GATES Bill & Melinda Gates Foundation
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (spike protein, SARS-CoV-2)
0 (Antigens, Viral)
0 (Spike Glycoprotein, Coronavirus)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20240220 Date Completed: 20240222 Latest Revision: 20240603
رمز التحديث: 20240603
مُعرف محوري في PubMed: PMC10879192
DOI: 10.1038/s41467-024-45404-x
PMID: 38378768
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-45404-x